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Summary.-Patients with head and neck cancer were treated with synchronous
radiotherapy and chemotherapy (vincristine, bleomycin and methotrexate). Before
treatment, mucositis was absent and low amounts of prostaglandin-like material
were extracted from peripheral plasma. As treatment proceeded mucositis occurred,
and its degree correlated with the amount of prostaglandin-like material extracted
from the plasma. Some patients were given moderate doses of drugs which inhibit
prostaglandin synthesis, but mucositis still occurred.
SYNCHRONOUS RADIOTHERAPY and che-
motherapy in the treatment of squamous-
cell carcinoma of the head and neck can
produceintenseinflammation ofthetreated
area (O'Connor et al., 1977). In a pilot
study, we have examined the part played
by prostaglandins, since these contribute
to the signs and symptoms of acute
inflammation (Vane, 1974). Elevated
amounts of prostaglandins or their meta-
bolites seem to be present in the blood or
excreted in the urine in some cancer
patients (see Bennett, 1979) and the
amounts ofprostaglandin-like material ex-
tracted from otherwise normal tissue in
animal experiments can be increased by
irradiation (Eisen & Walker, 1976, 1978)
or chemotherapeutic drugs (Levine, 1977).
In the opossum, radiation caused oesopha-
gitis which was inhibited by the prosta-
glandin-synthesis inhibitor indomethacin
and worsened by treatment with a stable
analogue of prostaglandin E2 (Northway
et al., 1980).
PATIENTS AND METHODS
We investigated 25 previously untreated
patients, referred to the Otolaryngology
Department of King's College Hospital, with
histologically provensquamous-cell carcinoma
of the head and neck. They comprised 21
males and 4 females aged 43-76 years (median
63 years) mostly with Stage III or Stage IV
tumours (11 patients each). The sites of the
primary carcinomas were as follows: larynx
10, oral cavity 7, oropharynx 3, cervical
oesophagus 2, paranasal sinus 2, undiscovered
1. Only some patients were studied at each
stage in the treatment.
About 10 ml of blood was drawn from an
antecubital vein of patients before and dur-
ing synchronous chemotherapy and radio-
therapy (O'Connor et al., 1977), a tourniquet
and a 21-gauge needle being used. A slow rate
of withdrawal (about 15 s) was used to mini-
mize damage to blood cells and the conse-
quent release of prostaglandin-like material.
The blood was transferred immediately
to a lithium heparin tube containing indo-
methacin (final concentration 10 ,ug/ml) to
inhibit subsequent prostaglandin synthesis,
and centrifuged at 1500 g for 10 min. The
plasma was extracted (Unger et al., 1971)
and bioassayed against PGE2, using the rat
gastric fundus strip preparation (Gilmore
et al., 1968). This method does not identify
the material, but quantifies it in terms of a
standard prostaglandin known to be formed
by many tissues, including macrophages.
The plasma prostaglandin-like material is
therefore expressed as picogram (pg) PGE2
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equivalents/ml, the lower limit of detection
usually being 10 pg PGE2 equivalents/ml
plasma. These values are sho-wn as ranges,
sometimes in parentheses preceded by the
median value, and all results are analysed
l)y Spearman's rank correlation.
Cancer therapy. Cancer treatment com-
prised 2-wAeekly pulses of chemotherapy, in-
tegrated with conventional radiotherapy
(total dose of 60-66 Gy over 6-7 weeks in
daily fractions of 2 Gy) using a cobalt unit
with a computer-planned beam (O'Connor et
al., 1977). Chemotherapy consisted of vin-
cristine (2 mg i.v.) followed 6 h later by
bleomycin (30 mg i.m.). At 24 h, methotrex-
ate (200 mg) wNas infused over 24 h, followed
by calcium leucovorin (15 mg i.m.) every
6 hx5. The first course of chemotherapy
(VBM1) was given before radiotherapy be-
gan, the second and third courses (VBM2 and
3) were usually given at about 20 and 40
Gy respectively, and VBM4 was given after
completion of radiotherapy. Initially the
patients were hospitalized only during the
treatment, but most remained as inpatients
after VBM3.
The intensity of a course of radiotherapy
can be represented as a number derived from
the length of treatment, the dose and its
fractionation (TDF; Orton & Ellis, 1973). The
normally accepted TDF for this type of
treatment without the addition of chemo-
therapy is 103, range 98-110, whereas TDF
values for the patients discussed in this paper
were usually lower (97, range 81-111),
mainly because the severity of both local
and general reactions necessitated a longer
treatment time and fewer fractions. Muco-
sitis is worse when chemotherapy is given
with radiotherapy, and this can delay opti-
mum treatment (O'Connor et al., 1977).
Mucositis.-Mucositis was assessed in the
clinic by one of us (N.S.B.T.) using visual
inspection, the pain reported by the patient,
and difficulty in swallowing (see Table).
Hospitalized patients with severe mucosal
discomfort were often prescribed aspirin
mucilage (1-2-1-8 g aspirin daily), paraceta-
mol with dextropropoxyphene (2-3 g para-
cetamol daily), or Mucaine, which contains a
surface anaesthetic, 3-5 h before blood sampl-
ing.
Those patients who received no prosta-
glandin-synthesis inhibitor within 12 h of
blood sampling are shown in the figures as
having had no drugs. Patients who took a
TABLE.-Estimnatian of mnucositis
Grade
O (none)
I (mild)
Signs/Symptoms
Alucosal re(lness xx ith miimal dis-
comfort
2 (modeiate) Altucosal redness A-ithl some muicosal
ulceration and substanitial dis-
comfort
,' (Severe) Atucosal redniess, extensive areas of
ulceration, mucli discomfort and
dysphagia, necessitating delay of
radiotherapy and sornetimes of
chemotherapy
prostaglandin-synthesis inhibitor, orwho were
prescribed a drug which was not recorded as
having been taken, are shown separately.
We do not know w%hether the outpatients
medicated themselves with non-steroidal
analgesics.
RESULTS
There were 54 measurements of pro-
staglandin-like material in plasma from
the 25 patients. No patient in the
pre-treatment group had mucositis, and
prostaglandin-like material was detected
in only 1 of the 17 plasma extracts
(10 pg/ml PGE2 equivalents).
Plasma samples (11 from 10 patients)
were taken 13 (1-30) days after finishing
VBM1, by which time the patients had
received 18 (2-28) Gy.
Prostaglandin-like material was detect-
ed in samples from 6 subjects (range 36-
430 pg/ml), and 3 of these patients had
mild mucositis.
Plasma samples (10 from 9 patients)
were taken 13 (1-20) days after finishing
VBM2, by which time the patients had
received 41 (20-56) Gy. Prostaglandin-
like material was detected in 7 samples
(range 165-4100 pg/ml). Mucositisoccurred
in 8 patients: 5 severe, 1 moderate, 2
mild. The patient without mucositis had
< 10 pg PGE2 equivalents/ml plasma.
Plasma samples (13 from 12 patients)
were taken 11 (1-28) days after finishing
VBM3, by which time the patients had
received 52 (41-60) Gy. Prostaglandin-
like material was detected in all these
plasma samples, ranging from 20 to 3900
pg/ml. Mucositis occurred in 11 patients:
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5 severe, 5 moderate, 1 ir
patient with no mucositis had
pg PGE2 equivalents/ml plasma
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DISCUSSION
Malignant tumours can release prosta-
glandin-like material into the bloodstream
(Stamford et al., 1980). In addition, many
tumours seem to release PG12 (Demers et
al., 1979; Hensby et al., 1980), a potent
vasodilator which is too unstable to survive
our extraction process. Prostaglandins
contribute to pain andinflammation (Vane,
1974) and their amounts increase when
cells are damaged. The side effect of
diarrhoea following pelvic irradiation is
relieved by aspirin, and so probably in-
volves prostaglandins (Mennie et al., 1975).
Radiation can increase the amount of
prostaglandin-like material extracted from
tissues (Eisen & Walker, 1976, 1978).
Furthermore, somechemotherapeuticdrugs
can release prostaglandins from cells
(Levine, 1977).
It would therefore be expected that
treatment given to patients with cancers
of the head or neck would raise the
amounts ofprostaglandins, which then con-
tribute to the signs and symptoms of in-
flammation. However, the amounts reach-
ing the peripheral blood from the tumour
would be reduced by metabolism in vari-
ous vascular beds. Many of the prosta-
glandins such as PGE2, which can be
bioassayed on rat gastric fundus, are
readily inactivated on passage through
the pulmonary circulation (Ferreira &
Vane, 1967). Perhaps we detected the
amounts released from the irradiated tu-
mour which escaped inactivation, but
another possibility is that the treatment
alters prostaglandin synthesis (e.g. by
macrophages) or degradation at other
sites. Eisen & Walker (1978) found that
whole-body X-irradiation of mice reduced
the activity of the prostaglandin-inacti-
vating enzyme prostaglandin-15-hydroxy-
dehydrogenase in various tissues. Alterna-
tively the treatment might increase
prostaglandin release from blood cells, or
even increase cell fragility so that they
release more prostaglandins as a result of
trauma due to sampling. The blood may
be affected by the chemotherapeutic
drugs, and also by the radiotherapy as it
flows through the region during irradia-
tion.
Regardless of the mechanism for the
increased amounts of plasma prostaglan-
din-like material, this work lays a logical
basis for the use of prostaglandin-syn-
thesis inhibitors in mucositis. However,
many patients receiving modest doses of
analgesics (e.g. aspirin 1 2-18 g daily)
developed mucositis during treatment, and
elevated amounts of prostaglandin-like
material were present in their plasma
extracts. It does not follow that the
aspirin was totally ineffective, because
patients with the worst signs and symp-
toms were most likely to receive anal-
gesic medication. Nevertheless, aspirin or
paracetamol, up to 1P8 and 3 g daily
respectively, did not give complete relief,
and higher doses or other drugs should be
tried. This aspect forms part of a double-
blind controlled trial which is now in pro-
gress with flurbiprofen, and is supported
by the relief of radiation-induced
oesophagitis in opossums with indometha-
cin, 2 or 4 mg/kg daily (Northway et al.,
1980). Prophylaxis may be better than
treatment started after mucositis has
occurred: prostaglandins can cause pro-
longed hyperalgesia in human skin
(Ferreira, 1972) and, if this occurs in the
mucosa, any relief by an inhibitor of
prostaglandin synthesis may be delayed.
Furthermore, non-steroidal anti-inflam-
matory drugs seem of prophylactic use in
headache (Bennett et al., 1978). Effec-
tive anti-inflammatory therapy would not
only improve patient well-being, but
would allow cancer treatment to be given
over the most effective period. However,
before recommending this it is desirable to
investigate the effect of anti-inflamma-
tory drugs on cancer growth and spread,
and the response to treatment. Some
studies in animals indicate that non-
steroidal anti-inflammatory drugs are of
benefit in these respects (Bennett, 1979)
but we must await the conclusion of our
trial with flurbiprofen to know whether
this drug is both safe and effective in
man.
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